Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | CASP1 | P29466 | 4/20 | 0.38 |
| ▸ | CASP7 | P55210 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272927 | 0.85 | CYP1A2 (0.45) | HCAR1DHFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1643374 | 0.84 | DHFR (0.49) | DHFRALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL28143388 | 0.81 | ALDH1A1 (0.49) | DHFRAKT1AKT2ALDH1A1CYP1A2 | |
| SCHEMBL28281841 | 0.80 | DHFR (0.49) | DHFRXDHPIK3CA | |
| SCHEMBL25422454 | 0.79 | MAPT (0.44) | DHFRALDH1A1HSD17B10USP2KDM4E | |
| SCHEMBL426848 | 0.77 | HCAR1 (0.49) | HCAR1ALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL25275632 | 0.77 | ALDH1A1 (0.47) | DHFRALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL4978113 | 0.76 | XDH (0.48) | HCAR1DHFRALDH1A1HSD17B10KDM4E | |
| SCHEMBL2195290 | 0.76 | HCAR1 (0.50) | HCAR1AKT1AKT2ALDH1A1CYP1A2 | |
| SCHEMBL16013034 | 0.74 | PIK3CD (0.34) | ALDH1A1KDM4EMAPTPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | HCAR1 983/4885DHFR 379/4885AKT1 2110/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | HCAR1 1419/4885DHFR 2877/4885AKT1 1549/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | HCAR1 1419/4885DHFR 2877/4885AKT1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.